Article Text

Download PDFPDF
Oestrogen plus progestin reduced risk of fracture in postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women, does oestrogen plus progestin reduce the risk of fracture?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★☆☆ Rheumatology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:

{allocation concealed*}.

Embedded ImageBlinding:

blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}.*

Embedded ImageFollow up period:

mean 5.6 years.

Embedded ImageSetting:

{40 US clinical centres.}

Embedded ImageParticipants:

16 608 women who were 50–79 years of age (mean age 63 y) and had an intact uterus. {Exclusion criteria included probable survival of <3 years, cancer in the past 10 years, and low haematocrit or platelet counts.}

Embedded ImageIntervention:

a single table of either conjugated equine oestrogen, 0.625 mg/day and medroxyprogesterone acetate, 2.5 …

View Full Text


  • * See glossary.

  • For correspondence: Dr J A Cauley, University of Pittsburgh, Pittsburgh, PA, USA.

  • Sources of funding: National Heart, Lung and Blood Institute and Wyeth-Ayerst Research.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd